Clinical Trials Logo

Filter by:
NCT ID: NCT02925884 Terminated - Dry Eye Clinical Trials

Effects of Gunnar Computer Glasses on Viewing Comfort and Performance

Start date: June 2013
Phase: N/A
Study type: Interventional

The proposed study aims to test if Gunnar computer glasses provide any advantages, in comparison to no glasses, on the following aspects in computer-related office work: - Any enhancement on visual performance of basic visual function, including visual acuity, contrast sensitivity, color discrimination, etc. - Any enhancement on visual performance of typical office work, including reading, word-spelling check, number searching, or target identification. - Any benefit in objective viewing comfort measured with viewing distance, blink frequency, post-viewing pupil size. - Any benefit in subjective viewing comfort reflected on the questionnaire of viewing symptom survey. - Any benefit in viewing comfort and visual performance with increased environmental ventilation or under strong glare. - Any benefit in life quality from daily wearing (e.g., better comfort or sleep quality).

NCT ID: NCT02925533 Terminated - Bladder Cancer Clinical Trials

Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Start date: December 14, 2016
Phase: Phase 1
Study type: Interventional

This research study is studying a combination of two experimental drugs as a possible treatment for Bladder Cancer that recurred after treatment with standard therapy, or Bladder Cancer that got worse while on treatment with standard therapy. The following interventions will be involved in this study: - B-701 - Pembrolizumab

NCT ID: NCT02924428 Terminated - Acne Vulgaris Clinical Trials

Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris

Start date: September 2016
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the efficacy of facial acne vulgaris treatment using the Venus Versa Diamondpolar applicator in combination with the Venus Versa AC dual applicator using two intense pulsed light wavelength bands.

NCT ID: NCT02924389 Terminated - HIV Clinical Trials

Dolutegravir in Reservoirs

Start date: September 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to find out how well the HIV medication dolutegravir gets into different parts of the body including blood plasma, special blood cells, and rectal tissue. Specifically, investigators want to compare how fast dolutegravir lowers the HIV viral load in these three different sites. In addition, as an exploratory aim, investigators seek to learn if there are any differences in how dolutegravir acts in males and females. Results of this study will provide more information about HIV medications and their limitations. In the future, this could help create better HIV medications that can get into these hard-to-reach places and eventually cure HIV infection.

NCT ID: NCT02924298 Terminated - Clinical trials for Chronic Kidney Disease

Effect of Sit Less, Interact, Move More (SLIMM) Regimen on Patients With Chronic Kidney Disease (CKD)

SLIMM
Start date: September 2013
Phase: N/A
Study type: Interventional

In the past two decades, the prevalence of obesity in the US has increased from 23.2% to 32.9%. This epidemic is fueling the Chronic Kidney Disease (CKD) epidemic. This likely is the major challenge facing the nephrology community in the next decade and beyond. This pilot study is designed to test the feasibility of the Sit Less, Interact, Move More (SLIMM) intervention and to determine its preliminary impact on light physical activity (PA) levels. Increasing light PA may have significant impact on both obesity and slowing the progression of CDK.

NCT ID: NCT02924194 Terminated - Parkinson's Disease Clinical Trials

Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease

Start date: September 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of deep brain stimulation of the nucleus basalis of Meynert (also called the "nbM") at improving memory in Parkinson's disease patients with mild cognitive impairments and memory difficulties. Patients with Parkinson's disease (PD) that are eligible for Deep Brain Stimulation (DBS) therapy for improvement of their motor symptoms and with evidence of mild cognitive impairments and memory difficulties will be enrolled.

NCT ID: NCT02924038 Terminated - Glioma Clinical Trials

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Start date: April 3, 2017
Phase: Phase 1
Study type: Interventional

This is a pilot, randomized, two arm neoadjuvant vaccine study in human leukocyte antigen-A2 positive (HLA-A2+) adults with World Health Organization (WHO) grade II glioma, for which surgical resection of the tumor is clinically indicated. Co-primary objectives are to determine: 1) the safety of the novel combination of subcutaneously administered IMA950 peptides and poly-ICLC (Hiltonol) and i.v. administered CDX-1127 (Varlilumab) in the neoadjuvant approach; and 2) whether addition of i.v. CDX-1127 (Varlilumab) increases the response rate and magnitude of CD4+ and CD8+ T-cell responses against the IMA950 peptides in post-vaccine peripheral blood mononuclear cell (PBMC) samples obtained from participating patients.

NCT ID: NCT02923830 Terminated - Clinical trials for Obstruction; Catheter, Infusion Catheter (Vascular)

Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes

Start date: April 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the safest and most effective flushing solution for maintaining patency (unobstructed flow) in BioFlo implanted port catheters. The complication rate in patients whose ports are flushed with saline only will be compared to the complication rate in patients whose ports are flushed with a combination of saline and heparinized saline.

NCT ID: NCT02923739 Terminated - Clinical trials for Recurrent Ovarian Carcinoma

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start date: May 5, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies the side effects of paclitaxel and bevacizumab with or without emactuzumab and how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back after treatment with platinum chemotherapy. Monoclonal antibodies, such as emactuzumab, block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may prevent the growth of new blood vessels that tumors need to grow. Giving emactuzumab with paclitaxel and bevacizumab may work better in treating ovarian, fallopian tube, or primary peritoneal cancer.

NCT ID: NCT02923531 Terminated - Clinical trials for Clear Cell Renal Cell Carcinoma

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

Start date: December 7, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab but not exhibiting a radiological response.